GoodGut has closed a €500,000 round of funding through the Capital Cell platform, raising 25% more than its initial goal. The funds will go towards finishing clinical validation of a non-invasive RAID-CRC test for colorectal-cancer screening using intestinal microbiota.

The company estimates that RAID-CRC will cut unnecessary colonoscopies by 30% and save up to €60 million per round of screening.

Mariona Serra, co-founder and CEO of GoodGut, is thankful to the more than 200 small investors, physicians and patients who have believed in the project. “This is the final push that will allow us to enter the valuable in vitro diagnostic market and make early diagnosis of colon and rectal cancer more efficient.”

Since it was established in 2014, GoodGut has gained CE marking for three products: RAID-Dx, the first non-invasive diagnostic test for Irritable Bowel Syndrome (IBS); RAID-Monitor, to monitor the progress of Inflammatory Bowel Disease (IBD); and TestUrGut, a non-invasive test that shows the health of a patient’s intestinal microbiota.

Recently, GoodGut signed a distribution deal with Palex Medical.

Over these years, the Scientific and Technologic Park of the University of Girona-based biotechfirm has raised more than €3 million in funding.

Photo: Mariona Serra shows new RAID-CRC test - © GoodGut